- Home
- MNPR vs DSGN Comparison
MNPR vs DSGN Comparison
Compare MNPR & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- DSGN
- Stock Information
- Founded
- MNPR 2014
- DSGN 2017
- Country
- MNPR United States
- DSGN United States
- Employees
- MNPR N/A
- DSGN N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- MNPR Health Care
- DSGN Health Care
- Exchange
- MNPR Nasdaq
- DSGN Nasdaq
- Market Cap
- MNPR 209.3M
- DSGN 208.9M
- IPO Year
- MNPR 2019
- DSGN 2021
- Fundamental
- Price
- MNPR $44.97
- DSGN $4.02
- Analyst Decision
- MNPR Strong Buy
- DSGN Hold
- Analyst Count
- MNPR 7
- DSGN 1
- Target Price
- MNPR $62.00
- DSGN $4.00
- AVG Volume (30 Days)
- MNPR 69.5K
- DSGN 97.8K
- Earning Date
- MNPR 08-08-2025
- DSGN 08-04-2025
- Dividend Yield
- MNPR N/A
- DSGN N/A
- EPS Growth
- MNPR N/A
- DSGN N/A
- EPS
- MNPR N/A
- DSGN N/A
- Revenue
- MNPR N/A
- DSGN N/A
- Revenue This Year
- MNPR N/A
- DSGN N/A
- Revenue Next Year
- MNPR N/A
- DSGN N/A
- P/E Ratio
- MNPR N/A
- DSGN N/A
- Revenue Growth
- MNPR N/A
- DSGN N/A
- 52 Week Low
- MNPR $1.72
- DSGN $2.60
- 52 Week High
- MNPR $54.30
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- MNPR 59.21
- DSGN 52.03
- Support Level
- MNPR $44.26
- DSGN $3.95
- Resistance Level
- MNPR $47.52
- DSGN $4.44
- Average True Range (ATR)
- MNPR 3.49
- DSGN 0.25
- MACD
- MNPR 0.54
- DSGN 0.02
- Stochastic Oscillator
- MNPR 64.49
- DSGN 54.35
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.